Literature DB >> 10079018

Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.

F Fierens1, P M Vanderheyden, J P De Backer, G Vauquelin.   

Abstract

Binding of the non-peptide angiotensin II AT1 antagonist [3H](2-ethoxy-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]- H-benzimidazoline-7-carboxylic acid ([3H]candesartan) to human angiotensin II AT1 receptor-transfected Chinese hamster ovary (CHO-AT1) cells was inhibited to the same extent by angiotensin II and non-peptide angiotensin II AT1 antagonists. No binding was observed in control CHO-K1 cells. Dissociation was slow (k(-1) = 0.0010+/-0.0001 min(-1)) after removal of the free [3H]candesartan but increased 5-fold upon addition of supramaximal concentrations of angiotensin II AT1 antagonists. Angiotensin II responses recovered equally slow from candesartan-pretreatment. When washed and further incubated, these angiotensin II responses also recovered more rapidly in the presence of 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphen yl-4-yl)methyl]imidazole (losartan), indicating that unlabelled ligands prevented reassociation. [3 H]candesartan saturation binding experiments required a long time to reach equilibrium. Therefore, the equilibrium dissociation constant (Kd = 51+/-8 pM) was calculated from the association and dissociation rate constants. Our findings indicate that the insurmountable nature of candesartan in functional studies is related to its slow dissociation from the receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079018     DOI: 10.1016/s0014-2999(98)00965-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.

Authors:  Peter Heusler; Christiane Palmier; Stéphanie Tardif; Sophie Bernois; Francis C Colpaert; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-27       Impact factor: 3.000

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

5.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 6.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

Review 7.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

8.  Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.

Authors:  P M Vanderheyden; I Verheijen; F L Fierens; J P DeBacker; G Vauquelin
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

9.  Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

Authors:  M T Le; M K Pugsley; G Vauquelin; I Van Liefde
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 10.  Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.

Authors:  Gustav G Belz
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.